Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs
1 Department of Animal Pathology, Faculty of Veterinary Medicine, Universidad de Las Palmas de Gran Canaria, Trasmontaña S/N, Arucas 35413, Las Palmas, Spain
2 Department of Veterinary Science, University Alma Mater of Bologna, via Tolara di Sopra 50, Ozzano dell’Emilia (BO), Italy
3 Departamento de Medicina y Cirugía Animal, Universidad CEU Cardenal Herrera, C/ Tirant lo Blanc, 7, 46117 Alfara del Patriarca Valencia, Spain
4 Fundación García Cugat, Madrazo 43, 08006 Barcelona, Spain
5 Instituto de Ciencias Biomédicas Universidad CEU Cardenal Herrera, C/del pozo s/n, 46115 Alfara del Patriarca Valencia, Spain
6 Artroscopia GC. Hospital Quirón Barcelona, Plaza Alfonso Comí, 12, Barcelona, Spain
BMC Veterinary Research 2013, 9:131 doi:10.1186/1746-6148-9-131Published: 2 July 2013
Adipose-derived mesenchymal stem cell (ADMSC) therapy in regenerative medicine is a rapidly growing area of research and is currently also being used to treat osteoarthritis (OA). Force platform analysis has been consistently used to verify the efficacy of different therapeutic strategies for the treatment of OA in dogs, but never with AD-MSC.
The aim of this study was to use a force platform to measure the efficacy of intraarticular ADMSC administration for limb function improvement in dogs with severe OA.
Eight lame dogs with severe hip OA and a control group of 5 sound dogs were used for this study. Results were statistically analyzed to detect a significant increase in peak vertical force (PVF) and vertical impulse (VI) in treated dogs. Mean values of PVF and VI were significantly improved after treatment of the OA groups, reaching 53.02% and 14.84% of body weight, respectively, at day 180, compared with only 43.56% and 12.16% at day 0.
This study objectively demonstrated that intraarticular ADMSC therapy resulted in reduced lameness due to OA.